CriticalMacrolide antibiotic×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
Clarithromycin is a strong inhibitor of the enzyme CYP3A4 (clarithromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and clarithromycin label, US Food and Drug Administration, FDA), and isavuconazole is a sensitive substrate of this enzyme (isavuconazole label, FDA). The two drugs have not been studied together. According to the European isavuconazole SmPC, clarithromycin may raise isavuconazole levels, but probably less than lopinavir with ritonavir, which increased isavuconazole exposure (area under the curve, AUC) by 96%. Ketoconazole, another strong CYP3A4 inhibitor, increased it by 422% (isavuconazole SmPC, European Medicines Agency, EMA). In the other direction, isavuconazole is a moderate CYP3A4 inhibitor and may raise levels of drugs that this enzyme metabolises (isavuconazole SmPC and label, EMA and FDA). Clarithromycin is both a substrate and an inhibitor of CYP3A (clarithromycin SmPC, AEMPS), but there are no measurements for this direction.
Symptoms
Higher isavuconazole levels may bring more adverse reactions (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). At three times the usual maintenance dose, headache, dizziness, tingling, numbness in the mouth, sleepiness, poor attention, taste disturbance, dry mouth, diarrhoea, vomiting, flushing, anxiety, restlessness, palpitations, fast heart rate, sensitivity to light and joint pain were more frequent (isavuconazole SmPC, EMA, and isavuconazole label, US Food and Drug Administration, FDA). Both drugs can cause liver injury, including fatal liver failure, and the signs of hepatitis listed for clarithromycin are loss of appetite, jaundice, dark urine, itching and a tender abdomen (clarithromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and isavuconazole label, FDA). QT prolongation has been reported with clarithromycin (AEMPS), while isavuconazole shortens the QT interval, more so at higher concentrations (EMA). The documents do not say how these effects combine.
Management
The US isavuconazole label contraindicates the combination: it contraindicates all strong CYP3A4 inhibitors. Clarithromycin is a strong CYP3A4 inhibitor according to its own documents and to the European isavuconazole SmPC (isavuconazole and clarithromycin labels, US Food and Drug Administration, FDA; clarithromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; isavuconazole SmPC, European Medicines Agency, EMA). The European isavuconazole SmPC names clarithromycin and is less strict than the US label: it keeps the isavuconazole dose unchanged but advises caution, because adverse reactions may increase (isavuconazole SmPC, EMA). The clarithromycin documents, in turn, advise caution with all drugs that CYP3A metabolises (clarithromycin SmPC and label, AEMPS and FDA). No document gives a waiting time between the two courses. The mean half-life of isavuconazole is 130 hours (FDA), and that of clarithromycin is 5 hours at 500 mg twice daily (clarithromycin SmPC, AEMPS). Evaluate liver tests at the start of and during isavuconazole treatment (FDA). If signs of hepatitis appear, stop clarithromycin at once (clarithromycin SmPC and label, AEMPS and FDA), and stop isavuconazole if signs of liver disease develop that may be due to it (FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Clarithromycin tablets (clarithromycin) prescribing information (2026)– FDA, DailyMed setid 4d42821d-ce7a-7d64-e063-6294a90a0875 (Solaris Pharma Corporation), version 2, revised 04/2026, sections 4, 5.2 and 7
- AEMPS: Ficha técnica: Claritromicina, Klacid 500 mg (nº registro 60515) (2024)– AEMPS, CIMA, nº registro 60515 (Klacid 500 mg comprimidos recubiertos con película), revisión 10/2024, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.5 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: CRESEMBA (isavuconazonium sulfate) prescribing information (2025)– FDA, DailyMed setid 8f7f73b8-586a-4df0-935f-fecd4696c16c (Astellas Pharma US), revisión 04/2025 (versión 21), secciones 4, 5.1, 5.5, 7, 10 y 12.3